TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effect of Neoadjuvant Chemoradiotherapy on Exercise Capacity in Colrectal Cancer Patients
Brief Summary: Neoadjuvant chemoradiotherapy (NACRT) prior to surgery for lower gastrointestinal (colon and rectal) cancer is associated with improved survival, but also adversely affects physical fitness, potentially rendering patients unfit for major surgery or increasing the risk of adverse outcome (death and serious complications) after major surgery. The investigators aim to obtain pilot data showing that neoadjuvant chemoradiotherapy (NACRT)reduces objectively measured exercise capacity (fitness).


Options:
A: Arm Label: Rectal Cancer; Type: N/A; Interventions: N/A
B: Intervention Type: BEHAVIORAL; Name: exercise intervention; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: complementary or alternative medicine procedure; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: fatigue assessment and management; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: physical therapy; Assigned to Arm(s): N/A
C: Arm Label: Yoga Group A: Minimum Exposure; Type: EXPERIMENTAL; Interventions: Other: Yoga | Arm Label: Yoga Group B: Medium Exposure; Type: EXPERIMENTAL; Interventions: Other: Yoga | Arm Label: Yoga Group C: Maximum Exposure; Type: EXPERIMENTAL; Interventions: Other: Yoga | Intervention Type: OTHER; Name: Yoga; Assigned to Arm(s): Yoga Group A: Minimum Exposure, Yoga Group B: Medium Exposure, Yoga Group C: Maximum Exposure
D: Arm Label: Stressmanagement counselling; Type: OTHER; Interventions: Other: Stressmanagement | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Stressmanagement; Assigned to Arm(s): Stressmanagement counselling

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effect of Neoadjuvant Chemoradiotherapy on Exercise Capacity in Colrectal Cancer Patients
Brief Summary: Neoadjuvant chemoradiotherapy (NACRT) prior to surgery for lower gastrointestinal (colon and rectal) cancer is associated with improved survival, but also adversely affects physical fitness, potentially rendering patients unfit for major surgery or increasing the risk of adverse outcome (death and serious complications) after major surgery. The investigators aim to obtain pilot data showing that neoadjuvant chemoradiotherapy (NACRT)reduces objectively measured exercise capacity (fitness).


Options:
A: Arm Label: Exercise; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Exercise programme | Arm Label: No Exercise; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Exercise programme; Assigned to Arm(s): Exercise
B: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Exercise Intervention; Type: ACTIVE_COMPARATOR; Interventions: Other: Supervised exercise in hospital | Intervention Type: OTHER; Name: Supervised exercise in hospital; Assigned to Arm(s): Exercise Intervention
C: Arm Label: Rectal Cancer; Type: N/A; Interventions: N/A
D: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Exercise; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): Exercise

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Letrozole and CC Alone in an IUI Program in Women With Surgically Treated Minimal to Mild Endometriosis
Brief Summary: To evaluate pregnancy rates with letrozole and CC alone in an IUI program for women with recently surgically treated minimal to mild endometriosis.


Options:
A: Arm Label: Aromatase Inhibitors (AI); Type: ACTIVE_COMPARATOR; Interventions: Drug: Letrozole (aromatase inhibitor) | Arm Label: Clomiphene Citrate (CC); Type: ACTIVE_COMPARATOR; Interventions: Drug: Clomiphene Citrate | Arm Label: Follicle Stimulating Hormone (FSH); Type: ACTIVE_COMPARATOR; Interventions: Drug: Follicle Stimulating Hormone (gonadotropin) | Intervention Type: DRUG; Name: Letrozole (aromatase inhibitor); Assigned to Arm(s): Aromatase Inhibitors (AI) | Intervention Type: DRUG; Name: Clomiphene Citrate; Assigned to Arm(s): Clomiphene Citrate (CC) | Intervention Type: DRUG; Name: Follicle Stimulating Hormone (gonadotropin); Assigned to Arm(s): Follicle Stimulating Hormone (FSH)
B: Arm Label: "Individual" or "standard" rFSH dose; Type: ACTIVE_COMPARATOR; Interventions: Drug: rFSH drug dose | Arm Label: "Standard" rFSH dose; Type: ACTIVE_COMPARATOR; Interventions: Drug: "Standard" rFSH dose | Intervention Type: DRUG; Name: rFSH drug dose; Assigned to Arm(s): "Individual" or "standard" rFSH dose | Intervention Type: DRUG; Name: "Standard" rFSH dose; Assigned to Arm(s): "Standard" rFSH dose
C: Arm Label: Extended letrozole regimen; Type: EXPERIMENTAL; Interventions: Drug: Extended letrozole regimen | Arm Label: Clomiphene citrate regimen; Type: ACTIVE_COMPARATOR; Interventions: Drug: Clomiphene citrate regimen | Intervention Type: DRUG; Name: Extended letrozole regimen; Assigned to Arm(s): Extended letrozole regimen | Intervention Type: DRUG; Name: Clomiphene citrate regimen; Assigned to Arm(s): Clomiphene citrate regimen
D: Arm Label: Letrozole/IUI; Type: EXPERIMENTAL; Interventions: Drug: Letrozole/IUI | Arm Label: CC/IUI; Type: ACTIVE_COMPARATOR; Interventions: Drug: CC/IUI | Intervention Type: DRUG; Name: Letrozole/IUI; Assigned to Arm(s): Letrozole/IUI | Intervention Type: DRUG; Name: CC/IUI; Assigned to Arm(s): CC/IUI

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Program to Protect Young Children From Tobacco Smoke Exposure
Brief Summary: The goal of this research project is to develop and evaluate an intervention to reduce young child tobacco smoke exposure


Options:
A: Intervention Type: BEHAVIORAL; Name: SHS reduction intervention based on social cognitive learning theory; Assigned to Arm(s): N/A
B: Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: School-based Care; Type: EXPERIMENTAL; Interventions: Behavioral: School-based Care | Intervention Type: BEHAVIORAL; Name: School-based Care; Assigned to Arm(s): School-based Care
C: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Educational print materials and a coaching call | Intervention Type: BEHAVIORAL; Name: Educational print materials and a coaching call; Assigned to Arm(s): Intervention
D: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Intervention | Intervention Type: BEHAVIORAL; Name: Intervention; Assigned to Arm(s): Intervention

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Brief Motivational Interviewing to Reduce Child Body Mass Index
Brief Summary: BMi 2 is a study that tests a behavioral counseling approach to reduce obesity in children. Practitioners (Pediatricians, Nurse Practitioners) were randomly assigned to one of three groups. The first group continued with standard care; in group 2, each practitioner delivered four study Motivational Interviewing visits with the parent/caregiver, and in group 3 in addition to the practitioner, a registered dietitian delivered 6 Motivational Interviewing visits. The primary outcome will be the child's percentile BMI change between the baseline and 2-year follow-up. Secondary outcomes will include behavior change around fruits and vegetables, sweetened beverages and exercise. Our hypothesis is that there will be a larger decrease in BMI percentile for children in group 3 than in group 2, and that children in group 2 will have a decrease in BMI percentile when compared to group one.


Options:
A: Arm Label: Standard Care with Education Materials; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard Care | Arm Label: Moderate Dose Motivational Interviewing; Type: EXPERIMENTAL; Interventions: Behavioral: Moderate Dose Motivational Interviewing | Arm Label: Higher Dose Motivational Interviewing; Type: EXPERIMENTAL; Interventions: Behavioral: Higher Dose Motivational Interviewing | Intervention Type: BEHAVIORAL; Name: Standard Care; Assigned to Arm(s): Standard Care with Education Materials | Intervention Type: BEHAVIORAL; Name: Moderate Dose Motivational Interviewing; Assigned to Arm(s): Moderate Dose Motivational Interviewing | Intervention Type: BEHAVIORAL; Name: Higher Dose Motivational Interviewing; Assigned to Arm(s): Higher Dose Motivational Interviewing
B: Arm Label: Intervention- Lifestyle family based; Type: EXPERIMENTAL; Interventions: Behavioral: family based lifestyle and behavioral counseling | Arm Label: Information control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: counseling focused on the child | Intervention Type: BEHAVIORAL; Name: family based lifestyle and behavioral counseling; Assigned to Arm(s): Intervention- Lifestyle family based | Intervention Type: BEHAVIORAL; Name: counseling focused on the child; Assigned to Arm(s): Information control
C: Arm Label: Team PLAY Group; Type: EXPERIMENTAL; Interventions: Behavioral: Team PLAY | Arm Label: Standard Care Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Team PLAY; Assigned to Arm(s): Team PLAY Group
D: Arm Label: A: experimental; Type: EXPERIMENTAL; Interventions: Behavioral: Obesity-Children | Arm Label: (B): experimental; Type: EXPERIMENTAL; Interventions: Behavioral: Obesity-Children | Arm Label: (c): experimental; Type: EXPERIMENTAL; Interventions: Behavioral: Obesity-Children | Arm Label: (D): control group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Obesity-Children | Intervention Type: BEHAVIORAL; Name: Obesity-Children; Assigned to Arm(s): (B): experimental, (D): control group, (c): experimental, A: experimental

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Brief Motivational Interviewing to Reduce Child Body Mass Index
Brief Summary: BMi 2 is a study that tests a behavioral counseling approach to reduce obesity in children. Practitioners (Pediatricians, Nurse Practitioners) were randomly assigned to one of three groups. The first group continued with standard care; in group 2, each practitioner delivered four study Motivational Interviewing visits with the parent/caregiver, and in group 3 in addition to the practitioner, a registered dietitian delivered 6 Motivational Interviewing visits. The primary outcome will be the child's percentile BMI change between the baseline and 2-year follow-up. Secondary outcomes will include behavior change around fruits and vegetables, sweetened beverages and exercise. Our hypothesis is that there will be a larger decrease in BMI percentile for children in group 3 than in group 2, and that children in group 2 will have a decrease in BMI percentile when compared to group one.


Options:
A: Intervention Type: BEHAVIORAL; Name: Physical activity and diet; Assigned to Arm(s): N/A
B: Arm Label: Cognitive Behavioural Therapy (CBT); Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive Behavioural Therapy (CBT), Behavioral: Psycho-Education Program (PEP) | Arm Label: Psycho-Education Program (PEP); Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive Behavioural Therapy (CBT), Behavioral: Psycho-Education Program (PEP) | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioural Therapy (CBT); Assigned to Arm(s): Cognitive Behavioural Therapy (CBT), Psycho-Education Program (PEP) | Intervention Type: BEHAVIORAL; Name: Psycho-Education Program (PEP); Assigned to Arm(s): Cognitive Behavioural Therapy (CBT), Psycho-Education Program (PEP)
C: Arm Label: A: experimental; Type: EXPERIMENTAL; Interventions: Behavioral: Obesity-Children | Arm Label: (B): experimental; Type: EXPERIMENTAL; Interventions: Behavioral: Obesity-Children | Arm Label: (c): experimental; Type: EXPERIMENTAL; Interventions: Behavioral: Obesity-Children | Arm Label: (D): control group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Obesity-Children | Intervention Type: BEHAVIORAL; Name: Obesity-Children; Assigned to Arm(s): (B): experimental, (D): control group, (c): experimental, A: experimental
D: Arm Label: Standard Care with Education Materials; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard Care | Arm Label: Moderate Dose Motivational Interviewing; Type: EXPERIMENTAL; Interventions: Behavioral: Moderate Dose Motivational Interviewing | Arm Label: Higher Dose Motivational Interviewing; Type: EXPERIMENTAL; Interventions: Behavioral: Higher Dose Motivational Interviewing | Intervention Type: BEHAVIORAL; Name: Standard Care; Assigned to Arm(s): Standard Care with Education Materials | Intervention Type: BEHAVIORAL; Name: Moderate Dose Motivational Interviewing; Assigned to Arm(s): Moderate Dose Motivational Interviewing | Intervention Type: BEHAVIORAL; Name: Higher Dose Motivational Interviewing; Assigned to Arm(s): Higher Dose Motivational Interviewing

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 52 Weeks, Double Blind, Randomized, Placebo-controlled Trial Evaluating the Effect of Oral BIBF 1120, 150 mg Twice Daily, on Annual Forced Vital Capacity Decline, in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Brief Summary: Idiopathic Pulmonary Fibrosis (IPF) is a chronic disease of unknown cause that results in scarring of the lung and there is a high unmet medical need for effective treatment to halt lung function decline, delay or avoid exacerbation (flare-ups), and ultimately to reduce the death rate.

In a large Phase 2 trial (1199.30) (NCT00514683), investigating the effects of 52 weeks of treatment with BIBF 1120 in patients with IPF, a positive effect was seen on lung function of patients treated with high dose of BIBF 1120 compared to placebo.

Hence it is the purpose of this trial to investigate and confirm the efficacy and safety of BIBF 1120 at a high dose in treating patients with IPF, compared with placebo. The trial will be conducted as a prospective, randomised design with the aim to collect safety and efficacy data.

Respiratory function is globally accepted for assessment of treatment effects in IPF patients. The chosen endpoint (Forced Vital Capacity (FVC) decline) is easy to obtain and is part of the usual examinations done in IPF patients.


Options:
A: Arm Label: BIBF 1120; Type: EXPERIMENTAL; Interventions: Drug: BIBF 1120 | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: BIBF 1120; Assigned to Arm(s): BIBF 1120
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Other: Pulmonary Rehabilitation | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Pulmonary Rehabilitation; Assigned to Arm(s): 1
C: Arm Label: Exercise Training at Pulmonary Rehabilitation Program; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Pulmonary Rehabilitation | Arm Label: Standard Treatment for IPF; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Pulmonary Rehabilitation | Intervention Type: BEHAVIORAL; Name: Pulmonary Rehabilitation; Assigned to Arm(s): Exercise Training at Pulmonary Rehabilitation Program, Standard Treatment for IPF
D: Arm Label: 2403 mg/day pirfenidone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pirfenidone | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Pirfenidone; Assigned to Arm(s): 2403 mg/day pirfenidone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 52 Weeks, Double Blind, Randomized, Placebo-controlled Trial Evaluating the Effect of Oral BIBF 1120, 150 mg Twice Daily, on Annual Forced Vital Capacity Decline, in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Brief Summary: Idiopathic Pulmonary Fibrosis (IPF) is a chronic disease of unknown cause that results in scarring of the lung and there is a high unmet medical need for effective treatment to halt lung function decline, delay or avoid exacerbation (flare-ups), and ultimately to reduce the death rate.

In a large Phase 2 trial (1199.30) (NCT00514683), investigating the effects of 52 weeks of treatment with BIBF 1120 in patients with IPF, a positive effect was seen on lung function of patients treated with high dose of BIBF 1120 compared to placebo.

Hence it is the purpose of this trial to investigate and confirm the efficacy and safety of BIBF 1120 at a high dose in treating patients with IPF, compared with placebo. The trial will be conducted as a prospective, randomised design with the aim to collect safety and efficacy data.

Respiratory function is globally accepted for assessment of treatment effects in IPF patients. The chosen endpoint (Forced Vital Capacity (FVC) decline) is easy to obtain and is part of the usual examinations done in IPF patients.


Options:
A: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: BIBF 1120; Type: EXPERIMENTAL; Interventions: Drug: BIBF 1120 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: BIBF 1120; Assigned to Arm(s): BIBF 1120
B: Intervention Type: BEHAVIORAL; Name: Pulmonary Rehabilitation; Assigned to Arm(s): N/A
C: Arm Label: 2403 mg/day pirfenidone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pirfenidone | Arm Label: 1197 mg/day pirfenidone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pirfenidone | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Pirfenidone; Assigned to Arm(s): 1197 mg/day pirfenidone, 2403 mg/day pirfenidone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo
D: Arm Label: BIBF 1120; Type: EXPERIMENTAL; Interventions: Drug: BIBF 1120 | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: BIBF 1120; Assigned to Arm(s): BIBF 1120

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effect of Neoadjuvant Chemotherapy on Lactate Threshold in Patients With Surgically Resectable Upper Gastrointestinal Cancer.
Brief Summary: It is important to assess patients' fitness for major cancer surgery which carries a high risk of mortality. Patients with poor heart and lung function have a higher risk of death after major cancer surgery. Cardiopulmonary exercise testing, CPET, is an objective measure of patients' fitness. Most patients, before surgery to resect their cancer, undergo a period of chemotherapy. Chemotherapy often regresses the cancer but also has adverse effects on cell function. Our hypothesis is that chemotherapy alters patient fitness, as assessed by CPET, prior to major cancer surgery. Participating patients will undergo fitness testing by CPET before and after their chemotherapy, prior to their surgery.


Options:
A: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Exercise; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): Exercise
B: Arm Label: Patients Pre and Post-chemotherapy; Type: N/A; Interventions: N/A
C: Arm Label: Exercise; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): Exercise
D: Arm Label: Exercise; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Exercise programme | Arm Label: No Exercise; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Exercise programme; Assigned to Arm(s): Exercise

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pharmacist Intervention for Glycemic Control in The Community (The RxING Study)
Brief Summary: Background: Approximately 1.9 million Canadians are living with diabetes and this is estimated to increase by 75% over the next few decades. Pharmacists are front line primary healthcare professionals who see patients with diabetes frequently and in Alberta, they have been allowed to prescribe medications and order laboratory tests. As such, pharmacists could systematically identify poorly controlled diabetes patients and provide greater access to diabetes interventions to improve blood sugar control.

Objective: The aim of this study is to determine the effect of a community pharmacist intervention on blood sugar control in individuals with poorly controlled diabetes.

Project description:

100 adults with type 2 diabetes and uncontrolled blood sugar will be defined by the participating pharmacists. Blood sugar control is going to assessed using hemoglobin A1c test (a blood test to measure individual's blood sugar control over the last 3 months). This test requires obtaining a blood spot from the patient which will be obtained by pricking his/her fingertip. Based on the hemoglobin A1c test result the pharmacist will assess the patient's need for insulin glargine, if the patient needs insulin glargine the pharmacist is going to prescribe it for him/her and educate him/her on its use. Patients are going to be followed up closely by the pharmacists for 6 months with regular updates to the patients' family physicians. This multi-centre study should demonstrate pharmacists' ability to improve glycemic control and improve access to care.


Options:
A: Arm Label: Insulin glargine; Type: OTHER; Interventions: Drug: Insulin glargine | Intervention Type: DRUG; Name: Insulin glargine; Assigned to Arm(s): Insulin glargine
B: Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Nurse-led blood pressure clinic; Type: EXPERIMENTAL; Interventions: Other: Nurse-led blood pressure clinic | Intervention Type: OTHER; Name: Nurse-led blood pressure clinic; Assigned to Arm(s): Nurse-led blood pressure clinic
C: Arm Label: Advanced care; Type: OTHER; Interventions: Other: Advanced Care | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Advanced Care; Assigned to Arm(s): Advanced care
D: Arm Label: MEDIC; Type: EXPERIMENTAL; Interventions: Behavioral: Behavioral counseling and peer support, Behavioral: Interactive Education, Behavioral: Role modeling, Procedure: Pharmacologic case management | Arm Label: usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Behavioral counseling and peer support; Assigned to Arm(s): MEDIC | Intervention Type: BEHAVIORAL; Name: Interactive Education; Assigned to Arm(s): MEDIC | Intervention Type: BEHAVIORAL; Name: Role modeling; Assigned to Arm(s): MEDIC | Intervention Type: PROCEDURE; Name: Pharmacologic case management; Assigned to Arm(s): MEDIC

Answer: A